BA1202 / Luye Group - LARVOL DELTA

A Study of BA1202 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=78 | Recruiting | Sponsor: Shandong Boan Biotechnology Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CEACAM5

Anxin International: The performance of Boan Biological (06955) is expected to be greatly improved due to the heavy volume of various products and the imminent listing [Google translation] (Investing.com) - "BA2101 (long-acting IL4R monoclonal antibody) has entered Phase 1 clinical trials in China and is expected to complete Phase 1 clinical trials for SAD by the end of 2023; BA1106 (non-IL-2 blocking anti-CD25 monoclonal antibody) has entered Phase 1 clinical trials in China. It is expected to complete the Phase 1 SAD clinical trial in 2024; BA1105 (ADCC enhanced Claudin 18.2 monoclonal antibody) has entered the Phase 1 clinical trial in China, and is expected to complete the Phase 1 SAD clinical trial by the end of 2023; BA1301 (Claudin 18.2 ADC) has obtained IND approval is expected to start phase 1 clinical trial in the second quarter of 2023; BA1202 (CEA/CD3 double antibody) is expected to receive IND approval in the first half of 2023."

IND • New P1 trial • Gastrointestinal Cancer • Immunology • Oncology • Solid Tumor

A Study of BA1202 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=78 | Not yet recruiting | Sponsor: Shandong Boan Biotechnology Co., Ltd

Metastases • New P1 trial • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CEACAM5

Boan Biotech's BA1202 Approved for Clinical Trial (PRNewswire-Asia) - "Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been approved for a clinical trial by the Center for Drug Evaluation of China's National Medical Products Administration (NMPA)....BA1202 is intended for the treatment of solid tumors, including CEA-positive tumors such as advanced/metastatic colorectal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, and gastric cancer. The clinical trial approved for BA1202 is a multicenter, open-label, single-arm, and Phase 1 trial that evaluates the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of BA1202. The study consists of two phases: dose escalation and dose expansion."

New P1 trial • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Application Proof of Shandong Boan Biotechnology Co., Ltd (HKEXnews) - "'We were conducting the pre-clinical process research of BA1202 as of the Latest Practicable Date, and we plan to submit the IND application in the first half of 2023...BA1106 is an innovative CD25 fully human monoclonal antibody independently developed by us...CD25 antibody is a broad-spectrum immuno-oncology drug, with potential indications for cervical cancer, renal cancer, ovarian cancer, melanoma, pancreatic cancer, hepatocellular carcinoma, gastric cancer and breast cancer...We were conducting non-clinical studies of BA1106 as of the Latest Practicable Date, and we plan to submit the IND application in the third quarter of 2022'."

IND • Preclinical • Oncology • Solid Tumor